Results 61 to 70 of about 111,447 (309)
Antihypertensive agents safety during pregnancy
The article discusses pregnancy course and labor outcomes in women with chronic hypertension. We divided all pregnant into two groups in dependence on the kind of antihypertensive treatment. The main group treatment was nebivalol monotherapy, the control
E V Karpova +6 more
doaj
Assessment and Management of Hypertension among Patients on Peritoneal Dialysis [PDF]
Approximately 7%-10% of patients with ESKD worldwide undergo peritoneal dialysis (PD) as kidney replacement therapy. The continuous nature of this dialytic modality and the absence of acute shifts in pressure and volume parameters is an important ...
Agarwal, Rajiv +3 more
core +1 more source
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source
CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2
Arterial hypertension (HT) takes leading position in the structure of morbidity and mortality among the cardiovascular diseases in the economically developed and developing countries of the world.
V. V. Popov, N. A. Bulanov, G. G. Ivanov
doaj +3 more sources
Antioxidant and antihypertensive activities of rice bran peptides [PDF]
Protein isolates and peptide fractions from food sources (cereal grains), have been shown to exert bioactive properties including antiobesity, anticancer, antiangiogenic, etc.
Hettiarachchy, Navam S. +2 more
core +2 more sources
Relationship between cardiovascular risk and lipid testing in one health care system: a retrospective cohort study. [PDF]
BackgroundThe US Preventive Services Taskforce (USPSTF) recommends routine lipid screening beginning age 35 for men [1]. For women age 20 and older, as well as men age 20-34, screening is recommended if cardiovascular risk factors are present.
Anderson, Melissa L +6 more
core +1 more source
Trends in first‐line monotherapy and combination therapy for hypertension in UK primary care
Aims Debate remains about the optimal initial treatment strategy for hypertension. Most guidelines recommend first‐line combination therapy for most patients. However, the UK's National Institute for Health and Care Excellence recommends first‐line monotherapy for all patients.
Kyle Johnson +4 more
wiley +1 more source
Background: Treatment with antihypertensives in patients with advanced cancer is often continued until very late in the disease trajectory, despite a considerable risk of hypotension.
Linda Björkhem-Bergman +3 more
doaj +1 more source
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr +18 more
wiley +1 more source
Aims Spontaneous reporting of adverse drug reactions (ADR) after a product has reached the market is essential for drug safety. This study analysed patient ADR reports and compared them with reports from the Japanese Adverse Drug Event Report (JADER) database to identify differences and trends.
Masami Tsuchiya +5 more
wiley +1 more source

